Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 5/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25830630 | 0.90 | KCNH3 (0.46) | KCNH3TAAR1 | |
| SCHEMBL18385065 | 0.90 | KCNH3 (0.46) | KCNH3TAAR1 | |
| SCHEMBL17130325 | 0.84 | IDO1 (0.53) | KCNH3TAAR1MEN1KMT2ARECQL | |
| SCHEMBL18385063 | 0.83 | EGFR (0.43) | — | |
| SCHEMBL17130308 | 0.83 | EGFR (0.43) | — | |
| SCHEMBL13223236 | 0.78 | CDC25B (0.48) | TAAR1MEN1KMT2A | |
| SCHEMBL18391971 | 0.78 | CDC25B (0.48) | TAAR1MEN1KMT2A | |
| SCHEMBL12387589 | 0.78 | SYK (0.48) | TAAR1MEN1KMT2A | |
| SCHEMBL17130323 | 0.78 | CDC25B (0.45) | TAAR1MEN1KMT2ARECQLMCL1 | |
| SCHEMBL10358543 | 0.75 | RECQL (0.69) | KCNH3TAAR1RECQLMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, ADAM8, TIE1 | KCNH3 4796/4885TAAR1 2020/4885MEN1 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.